Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

At 8.2% Global CAGR of Radiopharmaceutical Market Size and Share 2028 | Industry Analysis By Trends, Key Findings | Growth with USD 11.9 Bn: Forecast Report by Zion Market Research

This image opens in the lightbox

News provided by

Zion Market Research

21 Apr, 2022, 13:30 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, April 21, 2022 /PRNewswire/ -- As per Zion Market Research study, Radiopharmaceutical industry accrued ROI of approximately around US$ 5.8 billion in 2021 and is expected to gain income of almost US$ 11.9 billion in 2028.

Apparently, Radiopharmaceutical Market is set to register humungous gains of nearly 8.2% in time interval of 2022 to 2028. Moreover, expansion of radiopharmaceutical market over next six years is subject to humungous demand for nuclear drugs such as PET scans & SPECT scans for diagnosing ailments including cancer & other forms of chronic disorders during its preliminary phase. In addition to this, large-scale use of medical imaging techniques as a diagnostic method is enlarging scope of radiopharmaceutical industry surge. Furthermore, rise in diagnostic units in developed countries such as Canada, the U.S., Germany, and the UK will open new vistas of growth for radiopharmaceutical industry. Massive utility of 99m Tc radiopharmaceutical in neuroendocrine tumor imaging method as well as thyroid uptake pertechnetate will exalt industry landscape. Use of new technologies in nuclear imaging including PET and SPECT will enlarge market size. Nonetheless, massive costs incurred in producing radiopharmaceuticals in comparison to ROI can restrict growth of radiopharmaceutical industry.  

Key Industry Insights & Finding of the Radiopharmaceutical Market   Reports:

  • As per the analysis shared by our research analyst, the Radiopharmaceutical Market is expected to grow annually at a CAGR of around 8.2% (2022-2028).
  • Through the primary research, it was established that the Radiopharmaceutical Market was valued approximately USD 5.8 Billion in 2021 and is projected to reach to roughly USD 8.2 Billion by 2028.
  • North America over forecasting years can be attributed to rise in occurrence of chronic disorders such as heart ailments and cancer in countries such as the U.S.

Zion Market Research published the latest report titled as "Radiopharmaceutical Market - By Radioisotope Type (Technetium-99, Fluorine-18, Iodine-131, And Leutetium-177), By Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, And Nephrology), By Source (Cyclotrons And Nuclear Reactors), And By End-User (Hospitals And Diagnostic Labs): Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends And Forecast, 2022 – 2028." into their research database.

Radiopharmaceutical Market : Overview

Radiopharmaceuticals are a class of radioactive substances that can be utilized for therapeutic purpose or diagnostic purpose. Moreover, radiopharmaceuticals find large-scale applications in breast cancer and neuroendocrine tumors. In addition to this, the product also finds myriad utility in nuclear medicine. However, administration of radiopharmaceuticals is systemic and they are projected to be restricted to particular tissues owing to its bio-molecular features. Additionally, radiopharmaceuticals actively emit radiation and this makes their storage difficult in comparison to non-radioactive pharmaceuticals. This has restricted use of radiopharmaceuticals.  

Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.zionmarketresearch.com/sample/radiopharmaceutical-market

Our Free Sample Report Includes:

  • 2022 Updated Report Introduction, Overview, and In-depth industry analysis
  • COVID-19 Pandemic Outbreak Impact Analysis Included
  • 190 + Pages Research Report (Inclusion of Updated Research)
  • Provide Chapter-wise guidance on Request
  • 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
  • Includes Updated List of tables & figures
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
  • Zion Market Research methodology

Industry Dynamics:

Radiopharmaceutical Market : Growth Dynamics

  • Imaging techniques will embellish growth of radiopharmaceutical market

Rise in occurrence of ailments such as heart disorders, neurological ailments, and cancer will boost radiopharmaceutical market trends. Prominent surge in use of nuclear medicine in oncology has prompted demand for radiopharmaceuticals in recent years. In addition to this, launching of new technologies in nuclear imaging systems including PET and SPECT will prop up expansion of radiopharmaceutical industry. Nevertheless, huge costs of producing radiopharmaceuticals against ROI and strict laws governing radioactive emissions will put brakes on growth of radiopharmaceutical industry.

Furthermore, surge in research & development activities is projected to steer growth of radiopharmaceutical industry. Moreover, surge in patient awareness, need of precise diagnosis, and rise in use of molecular imaging techniques will embellish growth of radiopharmaceutical market. Use of monoclonal antibodies & radiolabeled peptides for identifying and treating malignant tumors will steer expansion of radiopharmaceuticals industry. Need for treating various kinds of diseases and massive use of targeted treatments such as radiopharmaceutical therapy will proliferate expansion of radiopharmaceutical market.

Radiopharmaceutical Market : Segmentation

  • Oncology Segment To Expand Rapidly Over Forecasting Timeline

Swift elevation of oncology segment in next six years can be credited to rise in occurrence of cancer across various age-groups of population. In addition to this, rise in use of PET methods for diagnosing cancer will have huge impact on growth of oncology segment. 

Directly Purchase a Copy of the Report @ https://www.zionmarketresearch.com/buynow/su/radiopharmaceutical-market

Breakthroughs in Radiopharmaceutical Market

  • In March 2022, GE Healthcare declared first patient dosed in its phase III clinical experiments for PET radiopharmaceutical imaging agents. It is likely to carry out clinical trial for SPECT radiopharmaceutical imaging agent in next phase. The strategic move is aimed at diagnosing adult population for Parkinson syndrome along with enhancing patient care services. Reportedly, GE Healthcare is planning to augment its radiopharmaceutical portfolio through these two pipeline radiopharmaceuticals, one for PET and another for SPECT. 
  • In March 2022, Novartis AG won approval of U.S. Food and Drug Administration for selling radiopharmaceutical for treating advanced stage of prostate cancer.
  • In April 2022, Iran has unleashed new generation of radiopharmaceutical referred as LU-177. It is developed by Iranian scientists and is used for diagnosing as well as curing various kinds of cancerous tissues. Moreover, LU-177 has ability to kill cancer tumor tissues by linking to tumor receptors. The mechanism of LU-177 is expected to prevent metastatis through disruption of circulating blood near tumors.

Technetium-99 To Lead Radioisotope Type Segment By 2028

Expansion of technetium-99 segment over next six years can be credited to use of the radioisotope for morphological imaging of internal body parts such as kidneys, liver, and bones. Apart from this, easy access of this radioisotope at reduced prices is set to produce huge demand for radioisotope in near future.

Get More Insight before Buying@: https://www.zionmarketresearch.com/inquiry/radiopharmaceutical-market

List of Key Players of Radiopharmaceutical Market  :

  • Jubilant Pharmova
  • Lantheus Holdings Inc.
  • Mallinckrodt Pharmaceuticals
  • Cardinal Health Inc.
  • GE Healthcare
  • Advanced Accelerator Applications
  • The Bracco Group
  • Eczacibasi-Monrol Nuclear Products
  • Nordion Inc.
  • Bayer AG
  • IBA Molecular Imaging Private Limited
  • Siemens Healthineers AG.

Key questions answered in this report:

  • What are the growth rate forecast and market size for Radiopharmaceutical Market ?
  • What are the key driving factors propelling the Radiopharmaceutical Market forward?
  • What are the most important companies in the Radiopharmaceutical Market Industry?
  • What segments does the Radiopharmaceutical Market cover?
  • How can I receive a free copy of the Radiopharmaceutical Market sample report and company profiles?

Report Scope:

Report Attribute

Details

Market size value in 2021

USD 5.8 Billion

Revenue forecast in 2028

USD 11.9 Billion

Growth Rate

CAGR of almost 8.2% 2022-2028

Base Year

2020

Historic Years

2016 - 2021

Forecast Years

2022 - 2028

Segments Covered

By Product Type, By Application, and By End Use

Forecast Units

Value (USD Billion), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2022 to 2028

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others

Companies Covered

Jubilant Pharmova, Lantheus Holdings Inc., Mallinckrodt Pharmaceuticals, Cardinal Health Inc., GE Healthcare, Advanced Accelerator Applications, The Bracco Group, Eczacibasi-Monrol Nuclear Products, Nordion Inc., Bayer AG, IBA Molecular Imaging Private Limited, and Siemens Healthineers AG.

Report Coverage

Market growth drivers, restraints, opportunities, Porter's five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.

Customization Scope

Avail customized purchase options to meet your exact research needs.  

https://www.zionmarketresearch.com/custom/86

Free Brochure: https://www.zionmarketresearch.com/requestbrochure/radiopharmaceutical-market

Regional Dominance:

  • North America To Make Notable Contributions Towards Regional Market Size By 2028

Expansion of radiopharmaceutical market in North America over forecasting years can be attributed to rise in occurrence of chronic disorders such as heart ailments and cancer in countries such as the U.S. In addition to this, surging aging populace and changing lifestyles   has resulted in obesity leading to huge sale of nuclear drugs. This has driven growth of regional market. Acceptance of new technologies for radioisotope production for treating chronic ailments will result in expansion of radiopharmaceuticals market in countries such as the U.S.  

Global Radiopharmaceutical Market is segmented as follows:

 Radiopharmaceutical Market: By Radioisotope Type Outlook (2022-2028)

  • Technetium-99
  • Fluorine-18
  • Iodine-131
  • Leutetium-177

Radiopharmaceutical Market: By Application Outlook (2022-2028)

  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Neurology
  • Nephrology

Radiopharmaceutical Market: By Source Outlook (2022-2028)

  • Cyclotrons
  • Nuclear Reactors

Radiopharmaceutical Market: By End-User Outlook (2022-2028)

  • Hospitals
  • Diagnostic Labs

Radiopharmaceutical Market   : By Region Outlook (2022-2028)

North America

  • The U.S.
  • Canada

Europe

  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Press Release For Radiopharmaceutical Market: https://www.zionmarketresearch.com/news/radiopharmaceutical-market-analysis

Browse Other Related Research Reports from Zion Market Research

  • Digital Pathology Market - Global Industry Analysis: The global digital pathology market was worth around USD 725.10 million in 2021 and is estimated to grow to about USD 1,493.66 million by 2028, with a compound annual growth rate (CAGR) of approximately 12.8 percent over the forecast period.
  • Healthcare Regulatory Affairs Outsourcing Market - Global Industry Analysis: The global Healthcare Regulatory Affairs Outsourcing Market accrued earnings worth approximately 5.23 (USD Billion) in 2020 and is predicted to gain revenue of about 12.14 (USD Billion) by 2028, is set to record a CAGR of nearly 11.7% over the period from 2021 to 2028.
  • Pharmaceutical Intermediates Market - Global Industry Analysis: The global Pharmaceutical Intermediates Market accrued earnings worth approximately 28,117 (USD Million) in 2020 and is predicted to gain revenue of about 39,779 (USD Million) by 2028, is set to record a CAGR of nearly 4.1% over the period from 2021 to 2028.

Browse through Zion Market Research's coverage of the Global Pharmaceutical Industry

Follow Us on: LinkedIn | Twitter | Facebook

About Us

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@zionmarketresearch.com 
Website: https://www.zionmarketresearch.com/ 
Blog - https://zmrblog.com/

Logo: https://mma.prnewswire.com/media/1605489/Zion_Market_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.